Creating Innovations and  transforming lives

Antibody engineering for promising drugs

A hope for finding a better tomorrow

Innovative research.  Transformative results.

Pioneering treatments for unmet needs

Dedicated to providing quality of life

What we do

We have developed a unique portal of humanized monoclonal antibodies as a subcutaneous treatment for rare diseases. Such rare diseases require attention as each patient deserves world class treatment. The humanized monoclonal antibodies are specific to the Complement Alternative Pathway (CAP) which plays an important role in the disease.  Classical Pathway remains fully functional for the control of the immune system. Unlike other drugs that are under development, our humanized monoclonal antibodies present state-of-the-art for treating rare forms of chronic diseases.
For treating complement-mediated diseases, the drug must be; selective for the CAP and must prevent formation and deposition of C3b and C5b-9, Our humanized monoclonal antibodies possess both such activities. Our humanized monoclonal antibodies bind the target proteins with picomolar affinity and selectively block the CAP by blocking the formation and deposition of C3b and C5b-9. Such properties are desirable in developing highly effective therapeutics for various rare diseases.
We have generated significant in vitro and in vivo pre-clinical and toxicological data which enabled us to file for an IND with the US FDA. Drug manufacturing process has been established and will be used to generate material for human clinical trial in 2018. We have created an exciting pipeline of therapeutic candidates especially for orphan diseases such as Paroxysmal Nocturnal Hemoglobinuria (PNH), C3-Glomerulopathy (C3G), and Neuromyelitis Optica (NMO). We believe that our portfolio of therapeutic antibodies has the potential for a better safety and efficacy profile than currently marketed drugs and those that are under development.
learn more

Research & development

Our R&D strategy is fully supported by multiple issued and ongoing US and international patents. Our know hows protect the selection, identification and development of therapeutic candidates that have made into the IND. We have streamlined our drug development path to enable the development of highly innovative therapeutic clinical antibodies.  Our portfolio of therapeutic antibodies have undergone a rigorous re-iterative selection process to identify the best-fit candidates to be used as a drug.
We have achieved remarkable success in advancing many antibodies that have a unique mechanism of action compared to other known research and commercial programs. Our success in preclinical, pharmacological, and toxicological studies is a testament to the quality of our lead selected candidates. These data together provides compelling evidence that our selected antibodies would have an excellent safety profile.  Our success in creating high concentration formulations along with longer half-life of our antibodies warrants the development of subcutaneously administered drug candidates providing easier dosing schedule for chronic indications. 
learn more

Product Pipeline

Explore our Science